The Hepatology Department of Henri Mondor Hospital is a reference center for the care of patients with hepatocellular carcinoma (HCC).
The specialized RCP "primary liver tumor" evaluates more than 30 HCC cases per week.
The Hepatology Department works in collaboration with the Departments of Oncology, Hepatobiliary Surgery, Nuclear Medicine, and Medical Imaging for the multidisciplinary management of patients with HCC.
Our goal is to test new molecules and innovative therapeutic procedures in the field of liver tumors, for example radioembolization.
Indeed, since 2007, numerous national and international phase 2 and 3 therapeutic trials (academic or industrial promotion) have been conducted in our department.
The CLIPP label "lymphoid tumors and primary tumors of the liver", awarded in 2015, led to the opening of a unit dedicated to early testing in collaboration with oncologists in April 2016, thus expanding the activity to phase 1 trials. This platform, dedicated to early testing, facilitates the design and implementation of early phase mono-centric trials.
The establishment of a cohort of patients with HCC is being initiated. More than 250 patients with HCC are supported each year at Mondor.
There are currently three areas of research:
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification
J Hepatol. 2017
Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis
Liver Int. 2017
Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas
BRAF V600E mutations in bile duct adenomas